AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Saroglitazar Mg: A Potent and Selective Peroxisome Proliferator-activated Receptor Alpha and Gamma Dual Agonist - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

March 16, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Mar 16, 2021--

The “Saroglitazar Mg - Emerging Insight and Market Forecast - 2030” report has been added to ResearchAndMarkets.com’s offering.

SAROGLITAZAR Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma dual agonist.

ADVERTISEMENT

“SAROGLITAZAR Mg - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Primary Biliary Cirrhosis in 7 Major Markets. A detailed picture of the SAROGLITAZAR Mg in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Zydus in January 2021, announced that the United States Food and Drug Administration (USFDA) has granted ‘Orphan Drug Designation’ (ODD) to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC). It is currently in Phase III of clinical trial for Primary Biliary Cirrhosis.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around SAROGLITAZAR Mg.
  • The report contains forecasted sales for SAROGLITAZAR Mg till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Primary Biliary Cirrhosis.
  • The report also features the SWOT analysis with analyst insights and key findings of SAROGLITAZAR Mg.

ADVERTISEMENT

SAROGLITAZAR Mg Analytical Perspective

In-depth SAROGLITAZAR Mg Market Assessment

This report provides a detailed market assessment of SAROGLITAZAR Mg in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

SAROGLITAZAR Mg Clinical Assessment

The report provides the clinical trials information of SAROGLITAZAR Mg covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Primary Biliary Cirrhosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence SAROGLITAZAR Mg dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Primary Biliary Cirrhosis are giving market competition to SAROGLITAZAR Mg and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SAROGLITAZAR Mg.
  • This in-depth analysis of the forecasted sales data of SAROGLITAZAR Mg from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAROGLITAZAR Mg.

Key Questions Answered

  • Which company is developing SAROGLITAZAR Mg along with the phase of the clinical study?
  • What is the technology utilized in the development of SAROGLITAZAR Mg?
  • What is the product type, route of administration and mechanism of action of SAROGLITAZAR Mg?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAROGLITAZAR Mg development?
  • What are the key designations that have been granted to SAROGLITAZAR Mg?
  • What is the forecasted market scenario of SAROGLITAZAR Mg?
  • What is the history of SAROGLITAZAR Mg and what is its future?
  • What is the forecasted sales of SAROGLITAZAR Mg in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to SAROGLITAZAR Mg?
  • Which are the late-stage emerging therapies under development for the treatment of the Primary Biliary Cirrhosis?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/qhafaz

View source version on businesswire.com:https://www.businesswire.com/news/home/20210316005531/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 03/16/2021 07:07 AM/DISC: 03/16/2021 07:07 AM

http://www.businesswire.com/news/home/20210316005531/en